Article information
Full text is only aviable in PDF
Bibliografía
[1.]
C.J. Murray, A.D. López.
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.
Lancet, 349 (1997), pp. 1498-1504
[2.]
A.D. López, K. Shibuya, C. Rao, C.D. Mathers, A.L. Hansell, L.S. Held, et al.
Chronic obstructive pulmonary disease: current burden and future projections.
Eur Respir J, 27 (2006), pp. 397-412
[3.]
Instituto Nacional de Estadística [consultado 02/11/2005]. Disponible en: http://www.inebase.es
[4.]
Mackay J, Eriksen M, editores. The Tobacco Atlas. Ginebra: World Health Organization, 2002 [consultado 2/11/2005]. Disponible en: www.who.int/tobacco/statistics/tobacco_atlas//en/print.html
[5.]
K.R. Chapman, D.M. Mannino, J.B. Soriano, P.A. Vermeire, A.S. Buist, M.J. Thun, et al.
The Global Burden of COPD: epidemiology and costs of COPD.
Eur Respir J, 27 (2006), pp. 188-207
[6.]
V. Sobradillo, M. Miravitlles, M.A. Jiménez, R. Gabriel, J.L. Viejo, J. Fernando, et al.
Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo.
Arch Bronconeumol, 35 (1999), pp. 159-166
[7.]
J.L. Izquierdo.
The burden of COPD in Spain: results from the Confronting COPD Survey.
Respir Med, 97 (2003), pp. S61-S67
[8.]
J.R. Banegas, L. Díez Gañán, J. González Enríquez, F. Villar Álvarez, et al.
La mortalidad atribuible al tabaquismo comienza a descender en España.
Med Clin (Barc), 124 (2005), pp. 769-771
[9.]
J.F. Masa, V. Sobradillo, C. Villasante, C.A. Jiménez-Ruiz, L. Fernández-Fau, J.L. Viejo, et al.
Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional.
Arch Bronconeumol, 40 (2004), pp. 72-79
[10.]
J.L. Izquierdo, J. De Miguel.
Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease.
J COPD, 1 (2004), pp. 215-223
[11.]
N.R. Anthonisen, M.A. Skeans, R.A. Wise, J. Manfreda, R.E. Kanner, J.E. Connett.
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Ann Intern Med, 142 (2005), pp. 233-239
[12.]
B.R. Celli, W. MacNee.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
Eur Respir J, 23 (2004), pp. 932-946
[13.]
J.A. Barberá, G. Peces-Barba, A.G. Agustí, J.L. Izquierdo, E. Monsó, T. Montemayor, et al.
Guía práctica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 37 (2001), pp. 297-316
[14.]
R.A. Pauwels, A.S. Buist, P.M. Calverley, C.R. Jenkins, S.S. Hurd, GOLD Scientific Committee.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[15.]
J. Vestbo, The TORCH Study Group.
The TORCH (Towards a Revolution in COPD Health) survival study protocol.
Eur Respir J, 24 (2004), pp. 206-210
[16.]
D.D. Sin, L. Wu, J. Anderson, N. Anthonisen, A.S. Buist, P.S. Burge, et al.
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease.
Thorax, 60 (2005), pp. 992-997
[17.]
J.M. Samet.
Inhaled corticosteroids and chronic obstructive pulmonary disease: new and improved evidence?.
Am J Respir Crit Care Med, 172 (2005), pp. 407-408
[18.]
A.L. Hansell, J.A. Walk, J.B. Soriano.
What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis.
Eur Respir J, 22 (2003), pp. 809-814
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica
